Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee

Proton therapy was first suggested in the management of lymphoma in 1974 as a way to spare the bone marrow when treating total nodal fields (1). However, interest in its use in lymphoma has grown only recently with the global growth in proton therapy centers, as well as with improvements in treatment delivery techniques. Hodgkin lymphoma (HL) is a rare malignancy, with approximately 8500 new cases annually in the United States, of which approximately 50% may ultimately receive radiation therapy (RT).